CTNNB1 and neoplasm: To validate our findings that IFNβ is mediating an anti-tumor immune response following LNP-CTNNB1 treatment (Figure 4f–g), we treated β-M mice with IFNβ 3x weekly for 5 weeks, which led to a significant decrease in tumor burden compared to vehicle controls (Figure 4h–j).